Razi Vaccine and Serum Research Institute, Agricultural Research Education and Extension Organization, Karaj, Iran.
Pasteur Institute of Iran, Tehran, Iran.
Viral Immunol. 2022 Jun;35(5):365-374. doi: 10.1089/vim.2021.0207. Epub 2022 May 6.
The effectiveness of inactivated H9N2 influenza vaccines is doubtful due to changes in antigenic regions of the virus hemagglutinin (HA) protein. One strategy for the development of the efficacious vaccine is the use of nanoparticles that display more immunogenic regions of the influenza virus. In this study, chitosan (CS)-based nanoparticles were developed as a delivery system for intranasal immunization using recombinant H9N2 virus HA1 and nucleoprotein (NP), for the induction of humoral and cellular responses. CS-HA1 and CS-NP nanoparticles were prepared by the ionic gelation method and characterized for their physicochemical properties and shape. The immunogenicity and the protective efficacy were evaluated by measuring antibody titers, T cell proliferation response, CD4/CD8 ratio, and quantitative real-time RT-PCR following intranasal administration of the prepared nanoparticles alone or in combination in chickens compared to an inactivated H9N2 vaccine. The average size, surface charge, and spherical structure of the synthesized nanoparticles showed high quality. Serologic analysis revealed that the immunization of inactivated vaccine groups resulted in strong influenza antibodies, which were significantly ( < 0.05) higher compared to the other groups. The vaccinated chickens with CS-HA1+CS-NP developed higher specific anti-influenza antibodies than in those vaccinated with each of rHA1 and rNP. Administration of a combination of the protein-based nanoparticles has stimulated the activation of both CD4 and CD8T cells and induced a significantly higher T cell proliferation. The viral shedding was significantly lower in CS-HA1+CS-NP and inactivated vaccine groups compared with other challenged groups. The data demonstrate the potential of CS-HA1+CS-NP nanoparticles for eliciting specific influenza antibodies and conferring protection in chickens.
由于病毒血凝素(HA)蛋白抗原区域的变化,灭活的 H9N2 流感疫苗的效果值得怀疑。开发有效疫苗的一种策略是使用展示流感病毒更多免疫原性区域的纳米颗粒。在这项研究中,壳聚糖(CS)基纳米颗粒被开发为使用重组 H9N2 病毒 HA1 和核蛋白(NP)进行鼻内免疫的递送系统,以诱导体液和细胞反应。通过离子凝胶化法制备 CS-HA1 和 CS-NP 纳米颗粒,并对其物理化学性质和形状进行了表征。通过测量抗体滴度、T 细胞增殖反应、CD4/CD8 比值以及定量实时 RT-PCR,评估了单独或组合鼻内给予这些纳米颗粒后的免疫原性和保护效力,与灭活的 H9N2 疫苗进行了比较。合成纳米颗粒的平均粒径、表面电荷和球形结构显示出高质量。血清学分析表明,灭活疫苗组的免疫接种产生了强烈的流感抗体,与其他组相比,显著(<0.05)更高。与单独接种 rHA1 和 rNP 的疫苗相比,接种 CS-HA1+CS-NP 的鸡产生了更高的特异性抗流感抗体。蛋白纳米颗粒的联合给药刺激了 CD4 和 CD8T 细胞的激活,并诱导了更高的 T 细胞增殖。与其他攻毒组相比,CS-HA1+CS-NP 和灭活疫苗组的病毒脱落显著降低。数据表明 CS-HA1+CS-NP 纳米颗粒具有在鸡中引发特异性流感抗体并提供保护的潜力。